GGrantIndex
Sort

82,697 grants matching vaccine development

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

$2,654,146
Pamela J Bjorkman · California Institute Of Technology · P01 · FY2022 · AI

NCI-Frederick Support and Technical Services

$2,653,485
Kristin Komschlies McConville · Office Of The Director, Nci · ZIC · FY2023 · CA

SPORE in Cervical Cancer

$2,651,995
Johns Hopkins University · P50 · FY2005 · CA

Durban International Clinical Trials Unit

$2,651,567
Umesh G Lalloo · Ukzn Innovation · U01 · FY2010 · AI

Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core

$2,651,134
Justin Ortiz · University Of Maryland Baltimore · N01 · FY2024 · AI

Center for Viral Systems Biology (CViSB)

$2,650,390
Kristian Graugaard Andersen · Scripps Research Institute, The · U19 · FY2023 · AI

Mechanisms of naturally-acquired immunity to malaria

$2,650,143
Peter Crompton · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Optimizing malaria transmission-blocking vaccines with improved platforms

$2,649,684
Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

SPORE in Prostate Cancer

$2,649,535
Baylor College Of Medicine · P50 · FY2005 · CA

Vanderbilt HIV Clinical Trials Unit (CTU)

$2,649,501
David W Haas · Vanderbilt University Medical Center · UM1 · FY2024 · AI

Southeastern Sexually Transmitted Infections Cooperative Research Center

$2,649,057
Philip Frederick Sparling · Univ Of North Carolina Chapel Hill · U19 · FY2011 · AI

Vaccine Induced Immunity in the Young and Aged

$2,649,051
Rafi Ahmed · Emory University · U19 · FY2018 · AI

Southeastern Sexually Transmitted Infections Cooperative Research Center

$2,648,826
Philip Frederick Sparling · Univ Of North Carolina Chapel Hill · U19 · FY2012 · AI

ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)

$2,646,688
Devanand Sarkar · Virginia Commonwealth University · P01 · FY2025 · CA

Reagent Resource Support Program for AIDS Vaccine Development

$2,646,088
Ronald Brown · Quality Biological, Inc. · N01 · FY2016 · AI

Soweto Clinical Trials Unit

$2,645,148
James Alasdair McIntyre · Wits Health Consortium (Pty), Ltd · U01 · FY2008 · AI

Columbia Collaborative HIV/AIDS Clinical Trials Unit

$2,644,556
Scott M Hammer · Columbia University Health Sciences · UM1 · FY2012 · AI

Herpesvirus Pathogenesis and Vaccine Development

$2,643,536
Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)

$2,642,740
Stephen A Spector · University Of California, San Diego · UM1 · FY2014 · AI

SPORE in Prostate Cancer

$2,640,179
Peter T Scardino · Sloan-Kettering Inst Can Research · P50 · FY2007 · CA

TASK ORDER B-15: Model Development and Medical Countermeasure Evaluation

$2,640,102
Anthony Griffiths · Boston University Medical Campus · N01 · FY2023 · AI

Paving the Way for a Novel Therapeutic Approach to Combat HIV

$2,640,000
Martin Prlic · Fred Hutchinson Cancer Research Center · DP2 · FY2012 · DE

HIV/SIV Data Base and Analysis Unit

$2,639,148
National Institute Of Allergy And Infectious Diseases · Y01 · FY2014 · AI

Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever

$2,639,002
Matthias Johannes Schnell · Thomas Jefferson University · N01 · FY2017 · AI

Host Pathogen Variation & TB Pathogenesis

$2,638,886
Thomas R Hawn · University Of Washington · U19 · FY2021 · AI